Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20666418 | 0.94 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BNQO2HSD17B1 | |
| SCHEMBL20666416 | 0.91 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BHSD17B1HSD17B2 | |
| SCHEMBL20667165 | 0.87 | ADORA2A (0.78) | ADORA2AADORA1ADORA2BNQO2HSD17B1 | |
| SCHEMBL20666417 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1HSD17B1HSD17B2FYN | |
| SCHEMBL20667171 | 0.86 | ADORA2A (0.77) | ADORA2AADORA1HSD17B1HSD17B2FYN | |
| SCHEMBL20666403 | 0.86 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BHSD17B1HSD17B2 | |
| SCHEMBL20666594 | 0.85 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BNQO2HSD17B1 | |
| SCHEMBL20666419 | 0.84 | ADORA2A (0.82) | ADORA2AADORA1SCN2AESR1ESR2 | |
| SCHEMBL20666405 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1HSD17B1HSD17B2FYN | |
| SCHEMBL20667173 | 0.84 | ADORA2A (0.81) | ADORA2AADORA1ADORA2BMAP4K4HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.